Eisai: Gilead Sciences Submits New Drug Application in Japan for Filgotinib for the Treatment of Ulcerative Colitis with an Inadequate Response to Conventional Therapies
- Written by: ACN Newswire - Press Releases
Read more //?#
.
Why the secrecy around car insurance?
Every year, millions of Australians receive their car insurance renewal and promise themselves they’ll look at it properly later. Then life gets in ...
Australian workers spend almost an hour a day administering email
Research finds email filing, searching and rework consuming an estimated 58 minutes a day and potentially exposing organisations to millionsAustralian...
Customer Service Is Becoming Part of the Small Business Sales and Marketing Engine
For Customer Service Week, 5-9 October, Thryv is urging small businesses to look beyond generating enquiries and examine what happens after a custome...
Gift Cards as the gateway to agentic payments
Prepaid and stored value gives consumers the trust and control to try AI shopping agents By Blackhawk Network VP Head of ANZ Kieran Nolan For deca...
Why Data Accumulation Without Governance Undermines Sustainability Goals
In July 2026, Group 2 entities, the second cohort of Australian businesses, began their first reporting period under the mandatory climate disclosur...
Permanent $20,000 Instant Asset Write-Off Gives Small Businesses Greater Planning Certainty
The Federal Government’s decision to permanently legislate the $20,000 instant asset write-off will give eligible small businesses greater certainty...